UK pharma stocks avoid selloff
3rd Apr 2025 10:18
(Sharecast News) - GSK and AstraZeneca avoided the selloff on Thursday as pharmaceutical products were exempt from Donald's Trump's tariffs.
Read moreAstraZeneca makes regulatory progress with Imfinzi, Calquence
31st Mar 2025 07:21
(Sharecast News) - AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its oncology therapies, Imfinzi and Calquence, marking progress in its immunotherapy and haematology pipelines.
Read moreAstraZeneca spending $2.5bn on new R&D centre, biotech deals in China
21st Mar 2025 11:17
(Sharecast News) - Pharma giant AstraZeneca announced on Friday that it is investing $2.5bn in a new global R&D centre in China, along with major research and manufacturing agreements with three of the country's biotech firms.
Read moreAstraZeneca buys biotech firm Esobiotec for up to $1bn
17th Mar 2025 07:21
(Sharecast News) - AstraZeneca announced on Monday that it is spending up to $1bn to acquire Belgian biotech firm EsoBiotec, which it says has the potential to "transform" cell therapy.
Read moreAstraZeneca hails trial results for imfinzi on gastric cancer
7th Mar 2025 07:03
(Sharecast News) - AstraZeneca said its Imfinzi drug when used with chemotherapy had shown "statistically significant and clinically meaningful improvement" in survival in resectable early-stage gastric and gastroesophageal cancers before surgery.
Read moreAstraZeneca's Imfinzi gets recommended for fresh EU approval
3rd Mar 2025 07:26
(Sharecast News) - AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and without EGFR mutations or ALK rearrangements.
Read moreAstraZeneca's camizestrant shows promise in breast cancer trial
26th Feb 2025 08:07
(Sharecast News) - AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in the first-line treatment of hormone receptor-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
Read moreLondon close: Stocks slip as US jobless claims rise
20th Feb 2025 16:06
(Sharecast News) - London equities ended lower on Thursday as investors reacted to a higher-than-expected rise in US jobless claims and a decline in UK consumer confidence.
Read moreUBS ups rating on AstraZeneca to 'buy'
13th Feb 2025 11:18
(Sharecast News) - UBS has upgraded AstraZeneca to a 'buy', citing the London-listed pharmaceutical firm's "sector-leading" drug pipeline.
Read moreMorgan Stanley sees huge upside at AstraZeneca
12th Feb 2025 10:21
(Sharecast News) - Morgan Stanley has initiated coverage of pharma giant AstraZeneca with an 'overweight' rating, recommending investors to build positions at a "compelling entry point".
Read moreRevenues, profits surge at AstraZeneca
6th Feb 2025 08:00
(Sharecast News) - AstraZeneca posted forecast-beating numbers on Thursday, fuelled by strong demand for its cancer and cardiometabolic drugs.
Read moreAstraZeneca's Imfinzi set for go-ahead by EU to treat lung cancer
3rd Feb 2025 07:02
(Sharecast News) - AstraZeneca's Imfinzi has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy.
Read moreAstraZeneca's Enhurtu gets new US approval
28th Jan 2025 07:03
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more hormone therapies.
Read moreAstraZeneca gets first US approval for cancer treatment Datroway
20th Jan 2025 07:30
(Sharecast News) - AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi Sankyo, for 'Datroway', or datopotamab deruxtecan, a treatment for adult patients with previously treated, unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer.
Read moreAstraZeneca's rare cancer drug Calquence gets US regulatory nod
17th Jan 2025 07:13
(Sharecast News) - AstraZeneca has announced that its Calquence drug has been approved in the US when used alongside chemoimmunotherapy for patients with previously untreated mantle cell lymphoma (MCL).
Read more